Kineta (NASDAQ:KA) vs. Antibe Therapeutics (OTCMKTS:ATBPD) Financial Review

Antibe Therapeutics (OTCMKTS:ATBPDGet Free Report) and Kineta (NASDAQ:KAGet Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Antibe Therapeutics and Kineta, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Antibe Therapeutics 0 0 0 0 N/A
Kineta 0 0 1 0 3.00

Kineta has a consensus price target of $8.00, indicating a potential upside of 1,521.07%. Given Kineta’s higher possible upside, analysts clearly believe Kineta is more favorable than Antibe Therapeutics.

Insider & Institutional Ownership

30.3% of Kineta shares are owned by institutional investors. 29.8% of Kineta shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Antibe Therapeutics and Kineta’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Antibe Therapeutics $7.51 million 5.94 -$14.54 million ($0.60) -0.19
Kineta $5.44 million 0.99 -$14.10 million ($1.38) -0.36

Kineta has lower revenue, but higher earnings than Antibe Therapeutics. Kineta is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Antibe Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Kineta has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Profitability

This table compares Antibe Therapeutics and Kineta’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Antibe Therapeutics -273.96% -150.49% -98.51%
Kineta N/A -453.89% -118.90%

About Antibe Therapeutics

(Get Free Report)

Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

About Kineta

(Get Free Report)

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy, which is in preclinical development for advanced solid tumors, such as renal cell carcinoma, ovarian, and colorectal cancers. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.